Preneoplastic lesions carry many of the antigenic targets found in cancer cells but often exhibit prolonged dormancy. Understanding how the host response to premalignancy is maintained and altered during malignant transformation is needed to prevent cancer. In order to understand the immune microenvironment in precursor monoclonal gammopathy of undetermined significance (MGUS) and myeloma, we analyzed bone marrow immune cells from 12 healthy donors and 26 MGUS/myeloma patients by mass cytometry and concurrently profiled transcriptomes of 42,606 single immune cells from these bone marrows. Compared to age-matched healthy donors, memory T cells from both MGUS and myeloma patients exhibit greater terminal-effector differentiation. However, memory T cells in MGUS show greater enrichment of stem-like TCF1/7 hi cells. Clusters of T cells with stemlike and tissue-residence genes were also found to be enriched in MGUS by single-cell transcriptome analysis. Early changes in both NK and myeloid cells were also observed in MGUS. Enrichment of stem-like T cells correlated with a distinct genomic profile of myeloid cells and levels of Dickkopf-1 in bone-marrow plasma. These data describe the landscape of changes in both innate and adaptive immunity in premalignancy and suggest that attrition of the bone-marrow-resident T cell compartment due to loss of stem-like cells may underlie loss of immune surveillance in myeloma.
Introduction:
Most human cancers are preceded by a long phase of premalignant lesions that are more common than the cancer itself. Multiple myeloma (MM) is a common hematologic malignancy wherein tumor cells grow predominantly in the bone marrow. All cases of MM are preceded by a precursor state termed as monoclonal gammopathy of undetermined significance (MGUS)(1). MGUS/MM is an attractive model to gain basic insights into early host response in human cancer as the precursor state is unresectable. Studies in mouse models have illustrated the capacity of the immune system to prevent, edit or sculpt early tumors, mediated at least in part by T cell recognition of neoantigens. In the setting of cancer, T cell exhaustion as well as other immune suppressive cells inhibit tumor immunity. However, as many neoantigens originate early during carcinogenesis, precisely when during carcinogenesis such exhaustion programs emerge and how these exhausted clones are maintained in human cancer/pre-cancer remain to be elucidated. Tumor cells in MGUS carry the great majority of genomic alterations, including the mutational burden found in MM (2) . Prior studies have demonstrated the capacity of T cells to mediate specific recognition of MGUS cells (3, 4) ; recent data also show alterations in innate lymphoid cells in these lesions (5) . Anti-tumor T cells are often enriched in the bone marrow of MM patients (6, 7) ; adoptive transfer of bone marrow T cells is being explored therapeutically in MM (8) . Recent prospective studies have shown that host immune response in MGUS can predict the risk of malignant transformation (9) . Data from humanized mouse models also suggest that dormancy of MGUS lesions is controlled by tumor-extrinsic factors (10) . Therefore, understanding the biology of immune cells infiltrating MGUS lesions may provide valuable insights into pathogenesis of MM.
One deficiency of existing studies is that only limited information on cell states and phenotypes of individual cells in the tumor microenvironment was obtained. To overcome these limitations, we performed high-dimensional single-cell RNA-sequencing (sc-RNA-seq) and mass cytometry analysis on immune cells in the MGUS/MM bone marrow microenvironment to gain deeper insights into these cells, both at transcriptome as well as proteomic level. We focused on the non-tumor compartment in both MM and MGUS and performed comparisons to immune cells in bone marrow from healthy donors.
Results:
In order to analyze immune cells in the bone marrow in MGUS/MM, we analyzed bone marrow mononuclear cells by mass cytometry utilizing 57 markers (clinical characteristics in Supplementary table S1, mass cytometry panel in Supplementary table S2). In view of the importance of CD8+ memory T cells in tumor immunity, we first examined the CD8+ memory T cell compartment which revealed a modest decline in CD8 central memory (T CM ) in MM (Figure1a). MM had slightly higher proportion of CD8+ effector/effector memory T cells (effector memory T EM + terminal effectors T TE ) (Figure1b). However, the proportion of terminal effectors expressing high levels of granzymeB was significantly increased in both MGUS and MM compared to age-matched healthy donors (Figure1c,1d, Supplementary FigureS1) .
In order to better characterize these changes in effector differentiation, we analyzed the expression of several T-cell-associated transcription factors in memory T cells. Of these, the expression of TCF1 was significantly increased among memory CD8+ T cells in the MGUS cohort, while the expression of T-bet, Eomes or GATA-3 did not differ (Figure1e,1f). A similar trend for increase in TCF1 expression was seen among CD4+memory T cells in MGUS (Supplementary FigureS2a) . The proportions of CD4+ T cells expressing Eomes and T-bet were also significantly lower in MGUS and MM cohorts (Supplementary FigureS2b) Together these data show that even though T cells infiltrating both MM and MGUS have enhanced effector differentiation, there are distinct differences in transcription factor expression in these cells.
Observed differences in the expression of TCF1 in premalignancy were of particular interest due to its emerging role in regulating T cell stemness in memory CD8+ T cells during chronic infections and possibly cancer (11) (12) (13) (14) . TCF1 expression in human T cells follows a distinct gradient, with stem-like features associated with TCF1 hi T-bet lo cells (14) . Utilizing similar gating strategy (Figure1g), the proportion of TCF1 hi cells was significantly increased in MGUS, while TCF1 negative cells were higher in MM (Figure1h). The increase in TCF1 hi CD8 T cells in MGUS was observed in both T CM and T EM compartments (Figure1i). TCF1 hi cells in all 3 patient cohorts had a distinct phenotype, with increased expression of CD127, CD27 and CXCR4 (marker of bone marrow homing), as well as reduced expression of T-bet, Eomes and lytic genes such as granzymeB (Figure1j). Thus, CD8 memory T cells infiltrating MGUS lesions are particularly enriched for phenotypes associated with enhanced stemness.
Analysis of the myeloid compartment (gating strategy in Supplementary FigureS3 ) was performed to identify markers differentially expressed between myeloid cells infiltrating MGUS and MM. These studies identified decline in the expression of CD95, CD86, c-kit and CD155 and an increase in PD-L1 expression on myeloid cells in MM compared to healthy donors, while there were no differences in other markers such as HLA-DR (Figure2a,2b) (Figure3a,3b, Supplementary Tables S3, S4 ). Several of these clusters were differentially represented between the 3 cohorts (Figure3c,3d) . Analysis of immune composition by scRNAseq correlated with mass cytometry data; for example, decline in B cells in MM by mass cytometry is also reflected in the decline in major B cell cluster (B1) in MM (Supplementary FigureS5, Figure3d ).
The most notable differences between T cells in MGUS and MM related to two distinct T cell clusters (clusters T2 and T3) (Figure4a). T cell cluster-2 (overrepresented in MGUS and reduced in MM) was characterized by increased expression of stem-like genes (TCF1/TCF7) consistent with data from mass cytometry, as well as genes associated with tissue residence (NR4A2, CD69) (15, 16) and reduced expression of lytic genes (granzymeA, granzymeK). In contrast, T cell cluster-3 (increased in MM) was characterized by the expression of lytic genes (e.g. granzymeA), senescence-associated genes (e.g. KLRG1) and proinflammatory cytokines (e.g. IL32) (Figure4b). Gene set enrichment analysis (GSEA) of these genes identified pathways related to effector functions and PD-1-mediated exhaustion programs as key pathway distinguishing MM-enriched clusters (Supplementary FigureS6). T cluster-2 enriched in MGUS was also enriched for pathways associated with stem cell memory cells (Supplementary FigureS6) as also suggested by mass cytometry data. While T cluster-3 is present in both healthy donors and MM patents, the T3 cluster in MM revealed enrichment of PRDM1 (as a marker of exhaustion), Fos, and CCL4 (as a marker of activation), and downregulation of granulysin and lysozyme (as a marker of dysfunction) (Supplementary Figure S7) . Taken together with the mass cytometry data (Figure1), these studies show that T cells in MGUS are enriched for stem-like memory T cells, overlapping in part with a quiescent tissue-resident phenotype, while those in MM show greater expression of lytic genes and senescence markers.
Myeloid cells comprised 3 distinct clusters that correlated with monocytes (M1), as well previously described CD1c+ or CD1c-dendritic cell clusters (M2, M3) (17) . Analysis of differentially expressed genes within myeloid clusters revealed reduced transcripts of HLA-DR in MM, consistent with less activated phenotype and consistent with the mass cytometry data showing lower CD86 as a marker of reduced activation in MM myeloid cells (Figure4c). Genes increased in MM myeloid cells also included several genes with possible implications for immunosuppressive properties (such as IL1R2, calcium binding proteins S100A8, S100A9, and S100A12), as well as other genes (e.g. versican), previously implicated in this role (18) . GSEA of differentially expressed genes identified dendritic cell activation as a pathway altered in these cells, supporting a role for altered antigen presentation (Supplementary Figure8). Cells from healthy donors and MM patients in the M1 cluster were located somewhat differently in in the tSNE plot (Figure 3c) . Top differentially expressed genes of cells in this cluster between healthy donors and MM patients also supported altered myeloid polarization with more immune suppressive phenotype of myeloid cells in MM (Supplementary Figure S9) .
In order to explore the link between T cell and myeloid changes, we examined the genomic profiles of myeloid cells from patients with higher proportion of cells in T2 cluster. Myeloid cells from these patients revealed a distinct genomic profile consistent with an enrichment for genes associated with TLR-mediated DC activation on GSEA (Figure4d, Supplementary Figure10 ). As TCF1 expression is known to be regulated by Wnt signaling, we hypothesized that the depletion of TCF1+ cells may be related to increase in Wnt-inhibitor Dickkopf-1 previously described in MM (19) . Consistent with this possibility, patients with elevated levels of Dickkopf-1 in the bone marrow plasma had reduced levels of TCF1+ memory T cells (Figure4e).
Discussion:
These data illustrate several changes in the immune landscape in MGUS and MM. The data show progressive increase in terminal effector T cells with progressive malignancy. However the finding that terminal effector T cells are increased even in MGUS suggests that alterations in T cell differentiation originate early in carcinogenesis during premalignancy.
An important and novel aspect of this paper is the finding that memory T cells in the bone marrow in MGUS are enriched for TCF1 hi memory T cells that bear resemblance to stem-like T cells (20) . TCF1 hi cells have to date been best studied in the context of models of chronic viral infections, wherein recent studies have illustrated their importance in preventing attrition of exhausted T cells and thereby maintaining long-term protective immunity (11, 12, 21) . TCF1 expressing cells have also been recently identified in human cancer tissue and were linked to outcome following checkpoint blockade in a small cohort (13, 22) . To our knowledge, these are the first studies to identify specific enrichment of these cells in the tumor microenvironment in a human premalignancy. It is now well established that many of the mutations/neoantigens found in cancer that serve as critical targets of tumor immunity originate during the premalignant phase, particularly in MM(1, 2). Therefore, the observed enrichment/persistence of these cells in MGUS may be key to maintaining tumor immunity during MGUS phase; loss of TCF1+ memory T cells in MM may lead to inability to maintain protective immunity over time and loss of immune surveillance. While the cells identified in our studies bear general resemblance to phenotypes observed in murine models of chronic viral infection, we and others (22) have not detected the expression of CXCR5 on these cells in the tumor tissue. Together, these data suggest that hierarchy of exhausted clones wherein a small subset of stem-like cells prevent clonal attrition is already evident at the premalignant stage.
In recent studies, we and others have shown an important role for tissue-resident memory in protective tumor immunity (16, 23, 24) . Similar cells were also identified in the human bone marrow and exhibit a quiescent phenotype with enrichment of transcription factors such as NR4A1 and NR4A2 implicated in inhibiting T cell differentiation and effector function (15, 25, 26) . Our data show that the T cell cluster enriched in MGUS shows features of both stem-like and tissue-resident memory, suggesting an overlap between these features of tumor-infiltrating T cells.
An important change in the MM tumor microenvironment relates to phenotype and gene expression in myeloid cells. Prior studies have shown that myeloid cells play an important role in regulating the growth of tumor cells (27, 28) . Altered phenotype of tumor-infiltrating myeloid cells including reduced expression of CD86, CD155, c-kit and increased PD-L1 supports an immunesuppressive phenotype. These data therefore support prior studies showing enrichment of myeloid cells in MM including their pro-tumor effects (18) . Reduced expression of Fas in MM myeloid cells is of interest, as Fas-FasL interactions play a major role in regulating myeloid cell kinetics as illustrated by increased myeloid progenitors in mice with mutated Fas/FasL (29) and may contribute to their enrichment in MM.
In addition to changes in T cells, we also observed changes in innate cells, with an increase in NK cells. NK cells in MM, however, revealed some functional alterations, such as decline in NKG2D. Therefore, alterations in innate lymphocytes appear to be an early feature in the evolution of gammopathies, which is consistent with prior studies (5, 30) . Recent studies suggest that innate cells may be targets for immune-modulatory drugs currently being explored for prevention of myeloma(5).
The enrichment of stem-like and resident T cells in the MGUS marrow that we observed may be impacted by local signals in the tumor bed. Prior studies have shown that local interactions with antigen-presenting cells in situ may be critical for tissue retention of murine T RM cells (31, 32) . Consistent with this, we observed that enrichment of stem-like/resident T cells correlated with distinct genomic features of myeloid cells indicative of TLR-mediated activation. Further studies are needed to dissect the signals needed for retention and persistence of these cells in the bone marrow. Some of the signals that regulate these cells may also be derived from tumors themselves. For example, as TCF1 expression may depend on Wnt signaling, Wnt inhibitor Dickkhopf-1 known to be increased in MM (19) may also contribute to the depletion of TCF1 expressing cells in MM. This hypothesis needs further study but is supported by the inverse correlation between Dickkhopf-1 levels in the marrow and TCF1 expressing cells.
In summary, these studies utilize complementary high-content single cell methods to gain novel insights into early changes in immune microenvironment in MGUS/MM with potential implications for immune therapy and prevention of MM. They illustrate early and complex alterations in the immune landscape in MGUS that includes both innate and adaptive immune cells (Supplementary FigureS11) . These data have several implications for immune-based approaches in MM. The presence of stem-like and resident T cells in tumor tissues has recently been linked to responsiveness to checkpoint blockade (22, 33) . Depletion of stem-like and resident T cells and predominant accumulation of terminal effectors in MM may therefore contribute to the lack of tumor regression following PD-1 blockade in MM (34), and may also limit the durability of responses following T cell redirection therapies. The finding that this increase in terminal effectors begins pre-symptomatically suggests the need to investigate even earlier stages (e.g. pre-MGUS)(1) to better understand the origins of altered T cell differentiation programs. Further studies in larger cohorts are needed to test whether the loss of stemlike/resident T cells is predictive of the risk of progression to clinical MM or durability of immune therapies and whether preemptive interventions before such depletion might be most effective at achieving durable remissions. Alternately, strategies that lead to an increase in stem-like and marrow-resident pool may be effective both in delaying attrition of T cell response in MGUS and its evolution to clinical MM, and may enhance the potential of durable remissions by engaging the immune system.
Methods:
Patients and samples Bone marrow samples were obtained from MGUS/MM patients following informed consent approved by the institutional review board. Mononuclear cells (MNCs) were isolated by density gradient centrifugation. Bone marrow specimens from healthy donors were purchased from All Cells Inc. Cells were cryopreserved in 90% FBS and 10% DMSO for long-term storage in liquid nitrogen.
Mass cytometry
Thawed bone marrow suspensions were stained with a 39 and 37 marker panel using metal conjugated antibodies according to manufacturer suggested concentrations (Fluidigm). Data on specific antibodies/clones is provided in Supplementary table S2. Cells were fixed, permeabilized, and washed in concordance with manufacturers cell surface and nuclear antigen staining protocol (Fluidigm). After antibody staining cells were incubated with intercalation solution, mixed with EQ Four Element Calibration Beads, and acquired with a Helios mass cyotometer (Fluidigm). Gating and data analysis was performed using Cytobank (https://www.cytobank.org/). Viable cells and doublets were excluded using cisplatin intercalator and DNA content with the iridium intercalator.
Single cell RNA-sequencing and data analysis Bone marrow mononuclear cells were thawed and flow sorted to obtain live cells (HD; n=8 and MGUS; n=14) and CD138 -live cells (MM; n=11). Barcoded libraries were prepared using manufacturer's (10x Genomics) protocol and sequenced with Illumina HiSeq. Reads were aligned, filtered, de-duplicated, and converted into a digital count matrix using Cell Ranger 1.2 (10X Genomics). Additional quality control (QC) and data analysis was performed using Seurat (35) . Cells with fewer than 200 unique sequenced genes or more than 10% mitochondrial genes were removed and cells with more than 7000 unique sequenced genes or more than 70000 unique molecular identifiers were removed to exclude potential doublets. Genes with the greatest dispersion in expression across cells were used in principal component analysis. Identified principal components were used for k-nearest neighbor unsupervised clustering with adjustment by the Jaccard similarity, and data was visualized using t-stochastic neighbor embedding (t-SNE). Differentially expressed genes defining clusters were manually inspected to determine cluster identity. Pathway analysis of differentially expressed genes in T or myeloid cells was performed using Gene Set Enrichment Analysis (GSEA) software from the Broad Institute.
Statistics
Statistical analysis of mass cytometry data was performed using 2D graphing and statistics software GraphPad Prism. Nonparametric Mann Whitney (for comparing two groups) and Kruskall Wallis (for comparing three groups) with a significance threshold of p<0.05 were used to compare different cohorts. Wilcoxon rank sum with a significance threshold of p<0.05 after Bonferroni correction was used to identify differentially expressed genes between clusters and disease states in the single cell RNA sequencing data. Chi square with a significance threshold of p<0.005 was used to identify clusters with differential composition by disease state. Data in bar graphs were plotted as mean + SEM.
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